antifungal drug resistance in sub-Saharan African populations: A systematic review.

: infections are responsible for increased morbidity and mortality rates in at-risk patients, especially in developing countries where there is limited access to antifungal drugs and a high burden of HIV co-infection.  This study aimed to identify antifungal drug resistance patterns within the subcontinent of Africa.  : A literature search was conducted on published studies that employed antifungal susceptibility testing on clinical isolates from sub-Saharan African countries using Pubmed and Google Scholar.

Multi-drug resistant oral Candida species isolated from HIV-positive patients in South Africa and Cameroon.

Candida species are a common cause of infection in immune-compromised HIV-positive individuals, who are usually treated with the antifungal drug, fluconazole, in public hospitals in Africa. However, information about the prevalence of drug resistance to fluconazole and other antifungal agents on Candida species is very limited. This study examined 128 Candida isolates from South Africa and 126 Cameroonian Candida isolates for determination of species prevalence and antifungal drug susceptibility.